Sichenzia Ross Ference LLP Represents Sunshine Biopharma, Inc. in $8 Million Private Placement
Press Release – New York, NY – March 15, 2022 – Sichenzia Ross Ference LLP today announced that it represented Sunshine Biopharma, Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs (NASDAQ: SBFM), in a $8.0 million private placement. The offering included 2,301,353 shares of common stock together with common warrants to purchase up to 2,301,353 shares of common stock, and 1,302,251 pre-funded warrants, together with common warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined offering price of $2.22, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $2.219. The common warrants have an exercise price of $2.22 per share. The gross proceeds to the Company from the offering were approximately $8.0 million.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Jeff Cahlon and David Manno and associate Michael Blane.
- Sichenzia Ross Ference LLP Represents ThinkEquity LLC in $6.87 Million Public Offering of Common Stock of Twin Vee PowerCats Co. - October 4, 2022
- Sichenzia Ross Ference LLP Represents Laidlaw & Company (UK) Ltd. in $5.75 Million Public Offering and Nasdaq Uplisting of Silo Pharma, Inc. - October 1, 2022
- Mid-Level Corporate Associate - September 29, 2022